PPARG and cardiac hypertrophy: Myostatin (MSTN) inhibits excessive cardiac autophagy by blocking AMPK/mTOR and miR-128/PPARγ/NF-κB signaling pathways, at least partially significantly inhibiting pathological cardiac hypertrophy and dysfunction [29].